Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Cited by 28 Publications

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

J Oncol, 2019, 2019:1805841

PubMed: 31275377 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

J Control Release, 2018, 269:245-257

PubMed: 29162480 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 433:210-220

PubMed: 30008386 ( click the link to review the publication )

Int J Oncol, 2018, 52(1):295-304

PubMed: 29115581 ( click the link to review the publication )

Cell Cycle, 2018, 17(10):1199-1211

PubMed: 29886801 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1404-1415

PubMed: 29479863 ( click the link to review the publication )

J Pharm Sci, 2018, 107(3):922-933

PubMed: 29162424 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:7031-7040

PubMed: 30410360 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5607-5614

PubMed: 30344715 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):523-535

PubMed: 27440269 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Neuro Oncol, 2017, 20(2):236-248

PubMed: 29016925 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:691-702

PubMed: 27823879 ( click the link to review the publication )

J Clin Invest, 2016, 126(5):1801-14

PubMed: 27043280 ( click the link to review the publication )

Eur J Pharm Biopharm, 2016, 104:7-18

PubMed: 27106606 ( click the link to review the publication )

Neurochem Res, 2016, 41(12):3192-3205

PubMed: 27632183 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):11443-56

PubMed: 27006309 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):467-72

PubMed: 26163089 ( click the link to review the publication )
PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1555-65

PubMed: 24501391 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(7):1740-7

PubMed: 23406775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

Methazolastone is a second-generation alkylating agent.

Targets

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kelly	NWLTXndPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW0PEBp		Mn\zTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN	MkjsNlU6PjB{OEK=
KellyCis83	NWHHPGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGPKbZQ1QCCq		NYnJ[Wc2UUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>?	NVWzeFVsOjV7NkCyPFI>
SK-N-AS	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGixd2w1QCCq		NWHtdotVUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>?	MlX1NlU6PjB{OEK=
SK-N-ASCis24	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3TBVlQ5KGh?		NIXwUWtKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>?	M4j3TFI2QTZyMkiy
CHP-212	NFfIPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{L0PFQ5KGh?		MY\JR\|UxRTdwOUhihKnDueLCiUCuOlkh\|ryP	NWrQbo5FOjV7NkCyPFI>
CHP-212Cis100	M3POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NU\mboFXPDhiaB?=		NYjFS2g5UUN3ME25MlU26oDLwsJihKkxNjh6IN88US=>	M1uyXFI2QTZyMkiy
U87	MX\GeY5kfGmxbjDBd5NigQ>?	M3HHNlExOCEQvF2=	MkPqNlQuPzJiaB?=		NIS1Z3lqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?=	MlWzNlU5ODh6Nki=
LN229	NEX0VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3kTnYxNTVyIN88US=>			M3rNSGlEPTB;MU[g{txO	M1jQS\|I2PzVyMkez
TR-LN229	NEHtS\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXnNE02OCEQvF2=			NWXZdGwxUUN3ME23O{DPxE1?	NXL5WnRwOjV5NUCyO\|M>
U87	NYTROY1wSXCxcITvd4l{KEG\|c3H5	NYK4dmdjOOLCk{KwNQKBkcL3TR?=	NGD5UHAzPCCq		M{W4WoVvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{	Moj4NlU3QDF4Nki=
U251MG	MVvBdI9xfG:\|aYOgRZN{[Xl?	NUD4OmcxOTBywrFOwG0>	MoK4OFghcA>?	NYPJcZo2WEKV	MXvpcoR2[2W\|IHHwc5B1d3Orcx?=	NYLLelI{OjV4OEC0OlQ>
U87MG	M{XoV2Fxd3C2b4Ppd{BCe3OjeR?=	MWGxNFDDqM7:TR?=	NX\xcodHPDhiaB?=	NYj0TolsWEKV	MmPFbY5lfWOnczDhdI9xfG:\|aYO=	M3n5bVI2PjhyNE[0
U87	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXX2PWQ6PTBvM{WwJO69VQ>?	MkLtOFjDqGkEoB?=		NUOzZXJycW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl?	NWfRSZdQOjV3NUSyNlM>
U118	M2HpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jHcVUxNTN3MDFOwG0>	NGLu[ZQ1QMLiaNMg		NILQTllqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	M3ewNFI2PTV2MkKz
U87	NYnGOHhtTnWwY4Tpc44hSXO\|YYm=	NF25VFUzPTBxM{WwJO69VQ>?	NUjjU\|FQPDkEoHlCpC=>		M2LPRYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>?	NVLiN2w3OjV3NUSyNlM>
U118	MmnFSpVv[3Srb36gRZN{[Xl?	NGjqb3UzPTBxM{WwJO69VQ>?	NF7jcXI1QMLiaNMg		NUnTOpN4\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn	NHT4SHAzPTV3NEKyNy=>
U87	NH3MSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vPU\|I2OC9\|NUCg{txO	NVXz[HdQPDkEoHlCpC=>		NF3VfZJqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS\|IwVcLiY3;0doVifGWmIIfpeIghXE2[	NH[2[owzPTV3NEKyNy=>
A375	NVnle5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnCOnVxPDkEoHlCpC=>		M2foPWlEPTB;Mk[1JO69VQ>?	M2O4SFI2PTJ2NUWy
A2058	NFXufYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlv6OFjDqGkEoB?=		NX7ldFZXUUN3ME2xNkDPxE1?	NHrlPZEzPTV{NEW1Ni=>
M238	NWHpXGNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1ix[VQ5yqCqwrC=		NHjhVYFKSzVyPUSwJO69VQ>?	MYmyOVUzPDV3Mh?=
M249	NV7hVWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnnUOFjDqGkEoB?=		M2TLWmlEPTB;MkW0JO69VQ>?	M17VeVI2PTJ2NUWy
M21	NF;m[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV74W4R{PDkEoHlCpC=>		Mn7jTWM2OD1{MkGg{txO	M4XERlI2PTJ2NUWy
U251	MULDfZRwfG:6aYT5JGF{e2G7	MkfHNlAh\|ryPwrC=	NIXiSZk1QMLiaNMg		NXvPWXBTemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=>	M3nnNFI2PDN2M{ix
LN229	NVXyS3lrS3m2b4TvfIl1gSCDc4PhfS=>	M{fmWVIxKM7:TdMg	NEjaWXQ1QMLiaNMg		M4niTJJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS=	MkD4NlU1OzR\|OEG=
U373MG-LUC	NGiwdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13pflczKGh?		M4HSPWlEPTB-NkCwJO69VQ>?	NELvZpozPTR\|MUm1Ny=>
U87	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXaNlUuOjByIN88US=>	M3u5ZVQ5yqCqwrC=		M{LPcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1\wb\|I2PDByN{S1
U251	NIT0WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzwRoxbOjVvMkCwJO69VQ>?	NGnOOWM1QMLiaNMg		NFjGcnRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIj3UoUzPTRyMEe0OS=>
U251	M1G1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSxNFAuPDByIN88US=>	MkDkO\|IwQTZiaB?=		NVHpb4RrfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	NIHIRo0zPTN5NUK3NS=>
U373	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXINVAxNTRyMDFOwG0>	MkfCO\|IwQTZiaB?=		MWL0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	MXmyOVM4PTJ5MR?=
U343	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKxNFAuPDByIN88US=>	M2PKRlczNzl4IHi=		NInNeop1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	NHHzc4QzPTN5NUK3NS=>
U87MG-luc2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYL6XIVIOTByLUSwNEDPxE1?	MkTzO\|IwQTZiaB?=		NGHBS2h1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	NVzKcFh[OjV\|N{WyO\|E>
U87	NXrv[Jd2TnWwY4Tpc44hSXO\|YYm=	NYq3WIVbOjByIN88US=>	NGflUIE1QCCq		NIHKO5dqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w	MYSyOVM{Pzd{MR?=
U251	NXm2T4JFTnWwY4Tpc44hSXO\|YYm=	MnO0NlAxKM7:TR?=	MlfEOFghcA>?		MmTMbY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	M4fsclI2OzN5N{Kx
A172	NGCyfpJHfW6ldHnvckBCe3OjeR?=	NVW5b5BEOjByIN88US=>	NV7iNmlXPDhiaB?=		MkO0bY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	NX;RW4o2OjV\|M{e3NlE>
U251	NVXIVmdoTnWwY4Tpc44hSXO\|YYm=	Mk\tNlAxKM7:TR?=	MWi0PEBp		MmTlbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>?	MVmyOVM{Pzd{MR?=
A172	NWHabGU5TnWwY4Tpc44hSXO\|YYm=	MknkNlAxKM7:TR?=	NWGx[o9DPDhiaB?=		NFu4TItqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{	Mn;oNlU{Ozd5MkG=
U87	MlnCSpVv[3Srb36gRZN{[Xl?	NH;6cpMzODBizszN	NV;teWxIOjRxN{KvNVIxKGh?		MoD2bY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6	NXXDfJVSOjV\|M{e3NlE>
U251	M3fDe2Z2dmO2aX;uJGF{e2G7	MoPMNlAxKM7:TR?=	NHnTSlQzPC95Mj:xNlAhcA>?		NH[xcFBqdmO{ZXHz[ZMh\|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl?	MUCyOVM{Pzd{MR?=
A172	MXTGeY5kfGmxbjDBd5NigQ>?	MXOyNFAh\|ryP	MWCyOE84Oi9zMkCgbC=>		MXrpcoNz\WG\|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk>	NH\GU2YzPTN\|N{eyNS=>
SNB19V	NH;aclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHv3fpM4KGR?	MWrEUXNQ	MmDsS2k2OD1\|NT63xtEyOiEQvF2=	NIjVdmIzPTJ5N{S0NS=>
SNB19M	NUfVXWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2jLZ\|ch\A>?	MV3EUXNQ	NV\qU25IT0l3ME20OlkvQcLzOEig{txO	M{ftb\|I2Ojd5NESx
SNB19VR	NEG3bIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4nzPFch\A>?	MX;EUXNQ	M3OxS2dKPTB;MkiwMlLDuTF6IN88US=>	NEjwfHYzPTJ5N{S0NS=>
U373V	M{G2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPDU2NQPyCm	NVjDdFFJTE2VTx?=	M2\zSWdKPTB;NkiuNOKyOzJizszN	MnrmNlUzPzd2NEG=
U373M	NXXIS\|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfLRZc4KGR?	M{K4TWROW09?	NFn2WFhIUTVyPUO2PE44yrF6NjFOwG0>	M4f0N\|I2Ojd5NESx
U373VR	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DqbFch\A>?	Ml3TSG1UVw>?	MWjHTVUxRTJ6OD64xtE{OyEQvF2=	NIfVUJYzPTJ5N{S0NS=>
U87MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUP4dVZSPyCm	NHe0TmtFVVOR	M3:wNGdKPTB;M{iuN:KyOjBizszN	Ml;sNlUzPzd2NEG=
HCT116	NInNXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MY[3JIQ>	Mlm3SG1UVw>?	MXHHTVUxRTV5OT65xtE{OiEQvF2=	MlXFNlUzPzd2NEG=
DLD1	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHDO{Bl	NUjmWFdVTE2VTx?=	M2TIWGdKPTB;NUCxMlTDuTl\|IN88US=>	M{L5elI2Ojd5NESx
MRC5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnybGk4KGR?	MnezSG1UVw>?	NYfLVHA3T0l3ME20OFkvPMLzODFOwG0>	NGr5TXAzPTJ5N{S0NS=>
SNB19V	Mni2SpVv[3Srb36gRZN{[Xl?	NGXCToYyODBizszNxsBVVVp?	Ml:4NE04OiCq		MV;pcoNz\WG\|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=>	NIfIXpozPTJ5N{S0NS=>
T98G	NWXkbHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPnOU8yOC9zNTFOwG0>	M{\nfFI1yqCq		MmWybY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS=	MofrNlUzPjJ7NkG=
U251	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rWVVUwOTBxMUWg{txO	M1q3SlI1yqCq		NIO4O2NqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=>	NH7tOmUzPTJ4Mkm2NS=>
T98G	NYXwSpAxTnWwY4Tpc44hSXO\|YYm=	NU\Ub\|h1OTVizszN	M{fTbVI1yqCq		M2flbIlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?=	MnT0NlUzPjJ7NkG=
U251	MX\GeY5kfGmxbjDBd5NigQ>?	NX;nfoxROTVizszN	NEiyflMzPMLiaB?=		NGLvbFlqdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO=	NVntWXZHOjV{NkK5OlE>
U-87 MG	NXzDOGZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjLTZJvPzJiaB?=		Mn\YTWM2OD1yLkmzJI1OyqB?	MkjKNlUzPDV\|M{K=
U-118 MG	NWPM[3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEK3fIU4OiCq		NFPvOmNKSzVyPUGuNFUhdU4EoB?=	MnT1NlUzPDV\|M{K=
U87	M{Tsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml\WNlQhcA>?		MYXJR\|UxRTJ4MD6zOEDPxE4EoB?=	M{PjZ\|I2OTd\|MkOz
U87 GSLCs	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn:xNlQhcA>?		M{fUR2lEPTB;N{[2MlEyKM7:TdMg	MX:yOVE4OzJ\|Mx?=
U87MG	NGK1VFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUC3NkBp		NVjYTHRyUUN3ME2xOU43OjVizszNxsA>	M{SySVI2ODVyOUG1
U251	M3\BT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVyxNFAuPDByIN88US=>	MoX3OFghcA>?	NHHPOoFFVVOR	NHfkc\|ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1XDfFI1PjJ\|N{O2
U87	NVTFVYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXuxNFAuPDByIN88US=>	NF73Rno1QCCq	NGLyS3VFVVOR	Mlm5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MXqyOFYzOzd\|Nh?=
MDA-MB-231-br	M{TvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnkXXExNTFyIN88US=>	MYS0PEBp	NVzJ[HFMTE2VTx?=	M321[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NX3mVFJVOjR4MkO3N\|Y>
HCC-1937	NVGyUXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:xUVAuOzByIN88US=>	NXWy[FNmPDhiaB?=	NXX4UYlGTE2VTx?=	Mne5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYCyOFYzOzd\|Nh?=
MDA-MB-231	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj4bWlyOC12MDFOwG0>	MYi0PEBp	MmnnSG1UVw>?	Mm\5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MmrCNlQ3OjN5M{[=
MDA-MB-468	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrR[GwxNTVyMDFOwG0>	MYm0PEBp	Mn3rSG1UVw>?	MknBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYiyOFYzOzd\|Nh?=
T47D	NX3Fe4x2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe3dJB[OC1zMECg{txO	NXS0UVN4PDhiaB?=	NXHxdnhjTE2VTx?=	MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NUnaTnVyOjR4MkO3N\|Y>
MCF7	NF20enJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT3NE0yODByIN88US=>	MWe0PEBp	MmGxSG1UVw>?	MoPZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVGyOFYzOzd\|Nh?=
Hs683	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP1Z48{OC1zMECwJO69VQ>?	MnTIPVYhcA>?		NWXN[WE2UUN3ME2xNlgvQSEQvF2=	NFvEcXAzPDR7NUmwOy=>
U87	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTuNE0yODByIN88US=>	MnvoPVYhcA>?		MWjJR\|UxRTF6LkS1JO69VQ>?	Mn3ONlQ1QTV7MEe=
LNZ308	NIixUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH3b2pHOC1zMECwJO69VQ>?	NGPZeXg6PiCq		MVXJR\|UxRTN{Nj63JO69VQ>?	M2\ZeFI1PDl3OUC3
U87	NETZZW9CeG:ydH;zbZMhSXO\|YYm=	NFu4NocyODBizszN	NFn3XWs1QCCq	NXP1PJB7TE2VTx?=	NEDseYdqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5	Mn\yNlQ1QDF3OE[=
U251	NGLCSlVCeG:ydH;zbZMhSXO\|YYm=	MXmxNFAh\|ryP	MUS0PEBp	NWHrRXdWTE2VTx?=	NGrv[nBqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5	MWqyOFQ5OTV6Nh?=
U251	M4j5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUD1d2tUOjRiaB?=		NIfjeppKSzVyPUi2MlI66oDLwsJihKkyNjV6IN88US=>	NHXxPHczPDN{Nkm1OC=>
U251	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MorUOFghcA>?		M1\pfWlEPTB;N{WuN\|TjiIoEsfMAjVEvODJizszN	MWKyOFMzPjl3NB?=
U251	NGrOZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorwO\|IhcA>?		NILLTZNKSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=>	NYLR[YhbOjR\|Mk[5OVQ>
U251	NV\mcJMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nJVVk3KGh?		MWjJR\|UxRTZ7Lkiy5qCKyrIkgJmzMlA1KM7:TR?=	M3PWV\|I1OzJ4OUW0
T98G	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjyNWh6OC15NUCg{txO	MmnqO\|IwQTZiaB?=		NHvkc2VqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MnLmNlQ{OjRyOEC=
U251-MG	NGTxTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnMeWwxNThyMDFOwG0>	MUK3NkBp		MonWbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHTXNoYzPDB7M{[zNC=>
D54-MG	NHfac5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFiyRpIxNThyMDFOwG0>	MmLhO\|IhcA>?		Mmq0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1Oxb\|I1ODl\|NkOw
SHG-44	MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XIOlExNTJyMDFOwG0>	MlzZPVYhcA>?		NXWwOWx5UUN3ME25Mlc{KMLzIEKuNVIh\|ryP	M1T2blI1ODZ3NU[5
U373	NHTFPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXWOJIyOC1{MECg{txO	NYjLbphsQTZiaB?=		M3XtO2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1?	MnfCNlQxPjV3Nkm=
HT-29	Mlz5SpVv[3Srb36gRZN{[Xl?	NFfZSlg2ODBizszN	NEOwXWMzPC92ODDo		M{n0SIVvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi	NX\CXW92OjRyM{iwOlg>
PC-3	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLmNE0zPSEQvF2=	MnPPOFghcA>?		MYjpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU>	Mny4NlM4PDZ7M{S=
PC-3	NV\sR4V6SXCxcITvd4l{KEG\|c3H5	NX[1bmxuOjVizszN	M3\JVlQ5KGh?		MkjYbY5lfWOnczDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l	NXPXW\|VlOjN5NE[5N\|Q>
T98G	NFPXRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljlOVAuPDByIN88US=>	NHvDU\|UyPDRiaB?=		M1u4cYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{Pu[\|I{PzF3NEm5
U87-MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTjO4pWOTByINM1US=>	NUDkfHFXPzJiaB?=		M4nWcolvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ?	NH3BNIozOzZ7Nke4PC=>
U251-MG	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T3VlExOCEEtV2=	NXXZUoFrPzJiaB?=		M4\WRYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ?	MYGyN\|Y6Pjd6OB?=
LNT-229	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDZN{0yODBizszN	MnjmNlQhcA>?		M4Xi[IlvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUmyN\|Y3PzZ\|Mh?=
T98G	NVj1eFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXSNVAuPzByIN88US=>	NH3UTG8zPCCq		NYjlTJp1cW6qaXLpeJMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NVXue4dxOjN4Nke2N\|I>
U87	NFjDVppHfW6ldHnvckBCe3OjeR?=	Ml3vNVAxKML3TR?=	Mm\qN{Bp		MU\lcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=>	M1H4R\|I{PjZ5NE[5
HCT116	NV\yVIpMTnWwY4Tpc44hSXO\|YYm=	MUWxNFAhyrWP	NWXZbFlMOyCq		M4rPRolv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w	NYPpTWdYOjN4Nke0Olk>
HCT3-6	MUHGeY5kfGmxbjDBd5NigQ>?	MVyxNFAhyrWP	MUOzJIg>		M{XwU4lv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w	NX\Wc2x[OjN4Nke0Olk>
U-87	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\0WlcxNTRyIN88US=>	NWm2NY9TOTJiZB?=		NX36Zmw3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NV\lOpI5OjN4NEW3Nlk>
U-87	M4W4SmFxd3C2b4Ppd{BCe3OjeR?=	MkfSNE01OCEQvF2=	NFLMb3A{NzZiZB?=		MVfpcoR2[2W\|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MViyN\|Y1PTd{OR?=
U-87	MYXGeY5kfGmxbjDBd5NigQ>?	MUSwMVQxKM7:TR?=	NWPrdohQOy94IHS=		NYC1NlVucW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NUfqZXp{OjN4NEW3Nlk>
GB-SCC010	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVO0JIQ>		M3LyO2lEPTB;MkK2JO69VQ>?	MWiyN\|YyOjd3NR?=
GB-SCC026	NYDVb5U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmrnOEBl		NGnpU3pKSzVyPUWzMlEh\|ryP	M3ey[lI{PjF{N{W1
GB-SCC028	NHXFXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnXrOEBl		MYrJR\|UxRTF4NzFOwG0>	NIjOeHgzOzZzMke1OS=>
U87	NV;zcpZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUHxc4VVPCCm		NV36WnkxUUN3ME20OU4zKM7:TR?=	NFX0XVAzOzZzMke1OS=>
U87 stem cell	NV\tUIRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWf2Wm9ZPCCm		NFf5NVRKSzVyPU[2Mlch\|ryP	M32xPVI{PjF{N{W1

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pERK / ERK / p-p38 / p38; PubMed: 24436439 Stem Cells Transl Med Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression. DR5 / c-FLIP / Survivin / XIAP; PubMed: 24436439 Stem Cells Transl Med Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours.	24436439
Growth inhibition assay	Cell viability; PubMed: 25751281 Mol Pharm Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X; PubMed: 27375225 Sci Rep Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). cleaved caspase-3; PubMed: 25663820 Cancer Cell Int Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).	27375225 25663820

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: L-1210 and L-1210/BCNU cells Concentrations: 0 μM -100 μM Incubation Time: l hours Method: L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells Formulation: 95% ethanol Dosages: 40 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: L-1210 and L-1210/BCNU cells
Concentrations: 0 μM -100 μM
Incubation Time: l hours
Method:
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

(Only for Reference)

Animal Research:

^[1]

+ Expand

Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
Formulation: 95% ethanol
Dosages: 40 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	38 mg/mL (195.72 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Temozolomide SDF

Molecular Weight	194.15
Formula	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04091503	Not yet recruiting	Drug: Intranasal Modified Temozolomide	Glioma Malignant\|Gliosarcoma\|Astrocytoma of Brain	Center Trials & Treatment Europe	December 10 2019	Phase 1
NCT03796507	Not yet recruiting	Drug: Temozolomide	Glioma of Brain	University of Rochester\|National Institutes of Health (NIH)	November 1 2019	Early Phase 1
NCT03932981	Recruiting	Drug: Temozolomide	Adult Brainstem Glioma	Assistance Publique - Hôpitaux de Paris	July 26 2019	Phase 2
NCT03709680	Recruiting	Drug: Palbociclib\|Drug: Temozolomide\|Drug: Irinotecan	Solid Tumors\|Ewing Sarcoma\|Rhabdoid Tumor\|Rhabdomyosarcoma\|Neuroblastoma\|Medulloblastoma\|Diffuse Intrinsic Pontine Glioma	Pfizer	May 24 2019	Phase 1
NCT03832621	Recruiting	Drug: Temozolomide\|Drug: Nivolumab\|Drug: Ipilimumab	Metastatic Colorectal Cancer	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	March 25 2019	Phase 2
NCT03935685	Recruiting	Drug: Mirtazapine (Remeron)	Glioma of Brain	University of California Irvine	February 26 2019	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended for dissolution.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Bleomycin Sulfate

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
Fluorouracil (5-Fluoracil, 5-FU)

Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.
Carboplatin

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide

Cited by 28 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Temozolomide SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide

Cited by 28 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Temozolomide SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)